Business
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently reported additional progress related to its proprietary, non-hallucinogenic neuroplastogen, MEAI.
About this update from Clearmind Medicine Inc.
[{"type":"text","content":"HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently reported additional progress related to its proprietary, non-hallucinogenic neuroplastogen, MEAI.","length":482,"tagName":"p"},{"type":"text","content":"In a world where obesity affects over a billion people globally, the search for truly transformative weight loss solutions has never been more urgent. Current blockbuster drugs like semaglutide and tirzepatide have revolutionized the treatment landscape by targeting gut-derived hormones that regulate appetite and metabolism. However, published studies and post-marketing experience indicate that these therapies may be associated, in certain patients, with gastrointestinal side effects, lean mass loss, tolerability challenges, high costs, and weight regain following discontinuation.","length":587,"tagName":"p"},{"type":"text","content":"Clearmind Medicine and its proprietary compound MEAI (5-Methoxy-2-aminoindane) - a next-generation, non-hallucinogenic neuroplastogen designed to explore new approaches to obesity treatment by potentially offering a novel therapeutic approach by disrupting rigid behavioral patterns, promoting cognitive flexibility, and increasing neuronal plasticity. while also delivering powerful metabolic benefits.","length":408,"tagName":"p"},{"type":"text","content":"A Revolutionary Mechanism: Targeting the Brain's Reward and Addiction Pathways","length":82,"tagName":"p"},{"type":"text","content":"Unlike GLP-1 and dual GLP-1/GIP agonists that primarily act on the gut and peripheral systems, and are reducing body weight while causing a lean soft tissue loss, MEAI works directly in the brain by modulating the monoaminergic system (and by substrate-type monoamine releasers, showing varying degrees of selectivity for SERT, NET, and DATs. This unique approach is also being studied to address compulsive eating behaviors, binge eating, emotional overeating, and food addiction - the often-overlooked psychological roots of obesity.","length":535,"tagName":"p"},{"type":"text","content...